Clinical trialPhase 2Unknown
A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- 22 May 2024
- Listed end
- 30 September 2026
- Enrollment
- 37 participants
- Sites
- 1
- Primary outcomes
- objective response rate (ORR)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 8 May 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To preliminarily evaluate whether there is a survival benefit of surufatinib combined with camrelizumab and mFOLFOX6 as the second-line treatment for advanced pancreatic cancer, and to explore the feasibility of second-line and post-line treatment for advanced pancreatic cancer
Detailed description public domain (ClinicalTrials.gov)
Second-line clinical study of surufatinib in combination with Caralizumab advanced pancreatic cancer